Thomas Powles
Impact in
- Pulmonary and Respiratory Medicine top 0.02%
- Renal cell carcinoma treatment
- Ferroptosis and cancer prognosis
- Cancer Research top 0.2%
- Cancer Genomics and Diagnostics
Papers in
-
- Renal cell carcinoma treatment 164
- Prostate Cancer Treatment and Research 5
-
- Cancer Genomics and Diagnostics 31
- Co-authors
- Axel Bex (53 shared papers)Börje Ljungberg (23 shared papers)Thomas B. L. Lam (20 shared papers)Lorenzo SO Marconi (22 shared papers)Alessandro Volpe (21 shared papers)Fabian Hofmann (18 shared papers)Saeed Dabestani (21 shared papers)Milan Hora (18 shared papers)
- Journals
- European Urology (33 papers)Annals of Oncology (18 papers)Clinical Genitourinary Cancer (10 papers)European Urology Oncology (9 papers)The Lancet Oncology (9 papers)
- Partner nations
- United KingdomUnited StatesFrance
In The Last Decade
Thomas Powles
191 papers receiving 25.5k citations
Thomas Powles's Hit Papers
Peers
Comparison fields: 5 of 126
- Pulmonary and Respiratory Medicine 17.3k
- Cancer Research 4.5k
- Oncology 7.6k
- Molecular Biology 7.2k
- Immunology 1.6k
Countries citing papers authored by Thomas Powles
This map shows the geographic impact of Thomas Powles's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Powles with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Powles more than expected).
Fields of papers citing papers by Thomas Powles
This network shows the impact of papers produced by Thomas Powles. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Powles. The network helps show where Thomas Powles may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas Powles, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 193 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2018 | 3643 |
| 2 | Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2019 | 2634 |
| 3 | EAU Guidelines on Renal Cell Carcinoma: 2014 Update Hit paper breakdown → | 2015 | 2278 |
| 4 | European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update Hit paper breakdown → | 2019 | 1113 |
| 5 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma Hit paper breakdown → | 2018 | 1011 |
| 6 | European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update Hit paper breakdown → | 2022 | 1008 |
| 7 | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2015 | 1004 |
| 8 | Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial Hit paper breakdown → | 2019 | 817 |
| 9 | Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial Hit paper breakdown → | 2016 | 778 |
| 10 | Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Hit paper breakdown → | 2019 | 643 |
| 11 | Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial Hit paper breakdown → | 2020 | 583 |
| 12 | Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma Hit paper breakdown → | 2021 | 547 |
| 13 | Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy Hit paper breakdown → | 2015 | 432 |
| 14 | Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial Hit paper breakdown → | 2020 | 410 |
| 15 | Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade Hit paper breakdown → | 2020 | 406 |
| 16 | Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial Hit paper breakdown → | 2020 | 372 |
| 17 | Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib Hit paper breakdown → | 2018 | 367 |
| 18 | Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study Hit paper breakdown → | 2014 | 334 |
| 19 | Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial Hit paper breakdown → | 2022 | 228 |
| 20 | 2018 | 222 |
About Thomas Powles
Thomas Powles is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Molecular Biology and Surgery, having authored 193 papers that have together received 25.9k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (164 papers), Renal and related cancers (41 papers), Cancer Genomics and Diagnostics (31 papers), Bladder and Urothelial Cancer Treatments (25 papers), Cancer Immunotherapy and Biomarkers (18 papers), Pancreatic and Hepatic Oncology Research (15 papers), Economic and Financial Impacts of Cancer (10 papers) and Prostate Cancer Treatment and Research (5 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (17.3k citations), Cancer Research (4.5k citations), Oncology (7.6k citations), Molecular Biology (7.2k citations) and Immunology (1.6k citations). Thomas Powles has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Axel Bex, Börje Ljungberg, Thomas B. L. Lam, Lorenzo SO Marconi, Alessandro Volpe, Fabian Hofmann, Saeed Dabestani, Milan Hora, Karim Bensalah and Michael D. Staehler. Their work appears in journals such as European Urology, Annals of Oncology, Clinical Genitourinary Cancer, European Urology Oncology and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.